<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput xmlns:ns2="local" id="84625" name="voxelotor"><HDS>Phase 3 Clinical</HDS><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="10">PRIME</RegulatoryDesignation><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation></RegulatoryDesignations><Actions><Action id="18854" type="primary">Hemoglobin alpha subunit modulator</Action><Action id="1546" type="secondary">Blood system agent</Action><Action id="2953" type="secondary">Anti-inflammatory</Action></Actions><Indications><Indication id="303" type="primary">Sickle cell anemia</Indication><Indication id="3771" type="secondary">Idiopathic pulmonary fibrosis</Indication></Indications><Entities><Entity>Chemical</Entity></Entities><OriginatorCompany id="1079834">Global Blood Therapeutics Inc</OriginatorCompany></ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput>